# reload+after+2024-01-23 11:46:46.487016
address1§100 Corporate Court
city§South Plainfield
state§NJ
zip§07080
country§United States
phone§908 222 7000
website§https://www.ptcbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
fullTimeEmployees§1402
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Matthew B. Klein F.A.C.S., M.D., M.S.', 'age': 51, 'title': 'CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 995399, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stuart W. Peltz Ph.D.', 'age': 63, 'title': 'Co-Founder, Senior Consultant & Member of Scientific Advisory Board', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1540540, 'exercisedValue': 0, 'unexercisedValue': 2334303}, {'maxAge': 1, 'name': 'Dr. Allan Steven Jacobson Ph.D.', 'age': 77, 'title': 'Co-Founder, Chairman of Scientific Advisory Board & Independent Director', 'yearBorn': 1946, 'fiscalYear': 2022, 'totalPay': 145000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Neil  Almstead Ph.D.', 'age': 56, 'title': 'Chief Technical Operations Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 829971, 'exercisedValue': 0, 'unexercisedValue': 1149948}, {'maxAge': 1, 'name': 'Mr. Eric  Pauwels', 'age': 62, 'title': 'Chief Business Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 847672, 'exercisedValue': 0, 'unexercisedValue': 1189813}, {'maxAge': 1, 'name': 'Mr. Pierre  Gravier M.S.', 'age': 38, 'title': 'Chief Financial Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine  Utter', 'age': 45, 'title': 'Senior VP, Chief Accounting Officer & Head of People Services', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 595537, 'exercisedValue': 995573, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Alex  Kane', 'title': 'Investor Relations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark Elliott Boulding', 'age': 62, 'title': 'Executive VP & Chief Legal Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 824094, 'exercisedValue': 355337, 'unexercisedValue': 1344115}, {'maxAge': 1, 'name': 'Ms. Jane  Baj', 'title': 'Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§2
compensationRisk§6
shareHolderRightsRisk§7
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.608
priceToSalesTrailing12Months§2.6377833
currency§USD
dateShortInterest§1702598400
forwardEps§-5.47
pegRatio§0.49
exchange§NMS
quoteType§EQUITY
shortName§PTC Therapeutics, Inc.
longName§PTC Therapeutics, Inc.
firstTradeDateEpochUtc§1371735000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e4477bd8-52de-3d5a-ae38-591eab6bb48f
gmtOffSetMilliseconds§-18000000
targetHighPrice§51.0
targetLowPrice§17.0
targetMeanPrice§28.92
targetMedianPrice§27.0
recommendationMean§2.9
recommendationKey§hold
numberOfAnalystOpinions§13
quickRatio§0.939
grossMargins§0.02131
ebitdaMargins§-0.39894
trailingPegRatio§None
